


Additional file 3: Sample size estimation for a future parallel group randomized controlled superiority trial (randomized in 1:1 ratio) powered at 80 % with a range of estimated relevant differences between groups. Estimations were based on the standard deviation (SD) of- and the correlation between the outcome at baseline and follow-up respectively with alpha=0.05 (see Table below). Calculations were carried out based on using the follow-up measure as outcome with adjustment for the outcome at baseline (similar to an analysis of co-variance).

Table: Change from baseline to follow-up for all participants in the SCREENS pilot trial


	Baseline (SD)	Follow-up (SD)	Change (SD)	Correlation
CARauc cortisol (nmol/L x minutes)	6.84 (2.97)	7.14 (3.02)	0.85 (1.46)	0.89
CARauc cortisone (nmol/L x minutes)	26.85 (7.47)	27.53 (6.81)	0.97 (3.69)	0.81
Peak-to-bed slope cortisol (nmol/L)	0.65 (0.32)	0.64 (0.33)	0.02 (0.21)	0.73
Peak-to-bed slope cortisone (nmol/L)	2.28 (0.73)	2.30 (0.82)	0.05 (0.39)	0.81

Data are presented as means with SD.


## Estimated sample size for CARauc cortisol



# Estimated sample size for CARauc cortisone



## Estimated sample size for Peak-to-bed cortisol slope



## Estimated sample size for Peak-to-bed cortisone slope

